✦ LIBER ✦

A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies

✍ Scribed by Edward F. McClay; Patricia D. Braly; Saeeda Kirmani; Steven C. Plaxe; Mary Eileen McClay; Linda Wilgus; Sinil Kim; Stephen B. Howell

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 580 KB
Volume: 74
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940715)74:2<664::aid-cncr2820740219>3.0.co;2-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II trial of dexverapamil, epirub

Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage–colony stimulating factor in patients with advanced pancreatic adenocarcinoma

✍ Gabriela Kornek; Markus Raderer; Thomas Schenk; Johann Pidlich; Franz Schulz; Se 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

Phase I study of escalating doses of mit

Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support

✍ Gini F. Fleming; Linda Janisch; Nicholas J. Vogelzang; Everett E. Vokes; Mark J. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB 👁 2 views

## BACKGROUND. Both paclitaxel and mitoxantrone demonstrate significant antineoplastic activity in breast cancer patients. Colony stimulating factor support allows significant dose escalation of each of these drugs when administered as a single agent. ## METHODS. We performed a Phase I study empl

A Phase I dose escalation of combination

A Phase I dose escalation of combination chemotherapy with granulocyte-macrophage–colony stimulating factor in patients with neuroblastoma

✍ M. Carmen Fernandez; Mark D. Krailo; Robert R. Gerbing; Katherine K. Matthay 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Phase I/II study of carboplatin and oral

Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer

✍ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

Phase I trial of paclitaxel, carboplatin

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that